Workflow
太龙药业(600222) - 2023 Q3 - 季度财报
TALOPHTALOPH(SH:600222)2023-10-26 16:00

Financial Performance - The company's operating revenue for Q3 2023 was CNY 448,959,882.99, representing a year-over-year increase of 3.55%[4] - The net profit attributable to shareholders for Q3 2023 was CNY 21,405,444.99, a significant increase of 168.07% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 16,554,967.74, up 154.36% year-over-year[4] - The basic earnings per share for Q3 2023 was CNY 0.0374, reflecting a 166.79% increase compared to the previous year[5] - Total operating revenue for the first three quarters of 2023 reached ¥1,442,869,622.59, an increase of 11.2% compared to ¥1,297,244,868.23 in the same period of 2022[16] - Total revenue from sales for the first three quarters of 2023 reached CNY 1,514,219,938.38, up from CNY 1,193,716,887.81 in the same period of 2022, representing an increase of approximately 27%[19] Assets and Liabilities - Total assets at the end of Q3 2023 were CNY 3,339,323,065.20, a decrease of 7.25% from the end of the previous year[5] - The equity attributable to shareholders at the end of Q3 2023 was CNY 1,450,960,475.16, down 7.61% from the previous year-end[5] - Total assets decreased to ¥3,339,323,065.20 as of September 30, 2023, down from ¥3,600,184,129.95 at the end of 2022, a reduction of 7.3%[16] - Total liabilities decreased to ¥1,847,351,755.37 from ¥1,986,099,689.13, marking a decline of 7.0%[15] - The company's equity attributable to shareholders decreased to ¥1,450,960,475.16 from ¥1,570,479,281.96, a decrease of 7.6%[16] Cash Flow - The company reported a net cash flow from operating activities of CNY -52,689,723.02 for the year-to-date, a decrease of 27.81%[4] - The net cash flow from operating activities for Q3 2023 was a negative CNY 52,689,723.02, an improvement from a negative CNY 72,992,203.41 in Q3 2022[20] - Cash and cash equivalents at the end of Q3 2023 were CNY 146,313,519.58, down from CNY 317,320,570.09 at the end of Q3 2022[21] - The company's cash and cash equivalents decreased to ¥181,546,019.58 as of September 30, 2023, down from ¥311,383,783.24 at the end of 2022, representing a decline of 41.7%[13] - Investment activities generated a net cash outflow of CNY 36,571,279.16 in Q3 2023, compared to a net inflow of CNY 148,273,305.58 in Q3 2022[20] - Financing activities resulted in a net cash outflow of CNY 19,146,761.48 in Q3 2023, an improvement from a net outflow of CNY 88,196,088.82 in Q3 2022[21] Expenses and Investments - The company incurred financial expenses of CNY 39,513,443.25 in Q3 2023, down from CNY 48,331,519.00 in Q3 2022, reflecting a decrease of approximately 18%[17] - R&D expenses for Q3 2023 were CNY 102,021,293.07, an increase from CNY 68,465,917.04 in Q3 2022, reflecting a growth of approximately 49%[17] - Total operating costs for the first three quarters of 2023 were ¥1,474,043,456.35, up from ¥1,325,971,247.56 in 2022, reflecting a year-over-year increase of 11.2%[16] Shareholder Information - The company has a total of 54,948 ordinary shareholders as of the end of the reporting period[9] - The financial support from the indirect controlling shareholder, Zhengzhou High-tech Investment Holding Group Co., Ltd., amounted to CNY 423.2 million as of the end of the reporting period[11] Profitability - The company reported a total comprehensive loss of CNY 80,045,343.84 for Q3 2023, compared to a loss of CNY 196,892,523.44 in Q3 2022, showing a reduction of about 59%[18] - The net profit for Q3 2023 was a loss of CNY 19,520,675.95, compared to a loss of CNY 58,267,787.03 in Q3 2022, indicating an improvement of about 66%[18] - The basic and diluted earnings per share for Q3 2023 were both CNY -0.0300, an improvement from CNY -0.1011 in Q3 2022[18] - The company reported a net profit margin decline, with undistributed profits decreasing to ¥169,683,600.07 from ¥186,609,951.83, a decrease of 9.5%[16]